CN104131108B - LncRNA biomarker is used in lineup's adenocarcinoma of lung and Human colorectal carcinoma diagnosis - Google Patents
LncRNA biomarker is used in lineup's adenocarcinoma of lung and Human colorectal carcinoma diagnosis Download PDFInfo
- Publication number
- CN104131108B CN104131108B CN201410397937.7A CN201410397937A CN104131108B CN 104131108 B CN104131108 B CN 104131108B CN 201410397937 A CN201410397937 A CN 201410397937A CN 104131108 B CN104131108 B CN 104131108B
- Authority
- CN
- China
- Prior art keywords
- primer
- seqidno
- sequence
- lncrna
- quantitative pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
The present invention relates to biological technical field, particularly relate to lineup's adenocarcinoma of lung and Human colorectal carcinoma diagnosis LncRNA biomarker, related kit and their purposes.The present invention provides lineup's adenocarcinoma of lung and/or Human colorectal carcinoma diagnosis LncRNA biomarker, and described LncRNA biomarker includes: uc001gzl.3, ENST00000434223, uc004bbl.1, ENST00000540136 and NR_034174.Human lung adenocarcinoma provided by the present invention and/or Human colorectal carcinoma diagnosis LncRNA biomarker, can be used to distinguish people's early stage adenocarcinoma of lung and Human colorectal carcinoma, it distinguishes the AUC of early stage adenocarcinoma of lung and pairing normal lung tissue up to 0.978, sensitivity and specificity respectively 92% and 98%.And its AUC of diagnosis for colorectal cancer sample also can reach 0.963, sensitivity and specificity respectively 94.4% and 88.9%.
Description
Technical field
The present invention relates to biological technical field, particularly relate to lineup's adenocarcinoma of lung and Human colorectal carcinoma diagnosis LncRNA biomarker, related kit and their purposes.
Background technology
Nonsmall-cell lung cancer is the first cause causing whole world cancer related mortality.It mainly includes four kinds of histological subtypes: adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other (neuroendocrine carcinoma, benign tumor etc.).The five year survival rate of nonsmall-cell lung cancer is lower than 15%, and early diagnosis can effectively reduce its mortality rate.Early stage detection adenocarcinoma of lung is even more important, because it is modal nonsmall-cell lung cancer type.Heredity and the molecule imbalance mechanism of understanding adenocarcinoma of lung are the keys for adenocarcinoma of lung early diagnosis.
Colorectal cancer is one of common malignant tumor of digestive tract, and for the 2nd frequently-occurring malignant tumor of west economy developed country, in China, colorectal cancer accounts for the 2nd of digestive tract cancer.Major part colorectal cancer patients early stage does not have symptom, and the patient more than 75% is already belonging to late period when making a definite diagnosis.Excavate the relevant new biomarkers of colorectal cancer and contribute to being further elucidated with its pathogenesis, also can provide novel targets for human colorectal diagnosis and treatment simultaneously.
Recent studies have shown that the subgenomic transcription of 90% becomes non-coding RNA.Non-coding RNA is considered as " transcribing noise " at first.But, increasing evidence shows that these non-coding RNAs have important biological action in many physiological processes.Non-coding RNA can be divided into short chain non-coding RNA (less than 200bp) and long-chain non-coding RNA (being longer than 200bp).Long-chain non-coding RNA (LncRNA) can be divided into antisense long non-coding RNA, intron non-coding RNA (LincRNA), and promoter is correlated with LncRNA and untranslated region LncRNA.Previous result of study shows, LncRNA plays an important role in various kinds of cell and biological process, for instance propagation, cell cycle, chromosome are reinvented and histone modification.It addition, their unconventionality expression is relevant to kinds of tumors, including breast carcinoma, gastric cancer, hepatocellular carcinoma and carcinoma of prostate.But, the relation between LncRNA biological function and expression and adenocarcinoma of lung and the colorectal cancer of LncRNA in adenocarcinoma of lung and colorectal cancer is also in the unknown stage.
Summary of the invention
The shortcoming of prior art in view of the above, it is an object of the invention to provide lineup's adenocarcinoma of lung and/or Human colorectal carcinoma diagnosis LncRNA biomarker, is used for solving the problems of the prior art.LncRNA biomarker provided by the present invention has significantly high sensitivity and specificity for human lung adenocarcinoma and Human colorectal carcinoma, especially people's early stage adenocarcinoma of lung and/or Human colorectal carcinoma had good Detection results, it is possible to be used for the detection of adenocarcinoma of lung and/or colorectal cancer as novel biomarker.
For achieving the above object and other relevant purposes, first aspect present invention provides lineup's adenocarcinoma of lung and/or Human colorectal carcinoma diagnosis to use LncRNA biomarker, and described LncRNA biomarker includes: uc001gzl.3, ENST00000434223, uc004bbl.1, ENST00000540136 and NR_034174.
Preferably, described human lung adenocarcinoma behaviour early stage adenocarcinoma of lung, described Human colorectal carcinoma behaviour early stage colorectal cancer.
The sequence of described uc001gzl.3 is such as shown in SeqIDNo:1；
The sequence of described ENST00000434223 is such as shown in SeqIDNo:2；
The sequence of described uc004bbl.1 is such as shown in SeqIDNo:3；
The sequence of described ENST00000540136 is such as shown in SeqIDNo:4；
The sequence of described NR_034174 is such as shown in SeqIDNo:5.
Preferably, described LncRNA biomarker also includes: ENST00000568243, uc001gch.1, NR_047562, ENST00000442037 and NR_038125.
The sequence of described ENST00000568243 is such as shown in SeqIDNo:6；
The sequence of described uc001gch.1 is such as shown in SeqIDNo:7；
The sequence of described NR_047562 is such as shown in SeqIDNo:8；
The sequence of described ENST00000442037 is such as shown in SeqIDNo:9；
The sequence of described NR_038125 is such as shown in SeqIDNo:10.
Second aspect present invention provides described LncRNA biomarker purposes in the diagnosing tumor medicine of preparation or screening human lung adenocarcinoma and/or Human colorectal carcinoma.
Third aspect present invention provides lineup's adenocarcinoma of lung and/or the combination of Human colorectal carcinoma diagnosis LncRNA primer, label, and described LncRNA primer includes: the reverse transcription primer of LncRNA, uc001gzl.3 primer, ENST00000434223 primer, uc004bbl.1 primer, ENST00000540136 primer, NR_034174 primer.
Preferably, the reverse transcription primer of described LncRNA is random primer.
Preferably, uc001gzl.3 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:11, primer after the sequence such as quantitative PCR shown in SEQIDNo:12；ENST00000434223 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:13, primer after the sequence such as quantitative PCR shown in SEQIDNo:14；Uc004bbl.1 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:15, primer after the sequence such as quantitative PCR shown in SEQIDNo:16；ENST00000540136 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:17, primer after the sequence such as quantitative PCR shown in SEQIDNo:18；NR_034174 primer includes before the sequence such as quantitative PCR shown in SEQIDNo:19 primer after primer, the sequence such as quantitative PCR shown in SEQIDNo:20.
Preferably, described label is SYBRGreen.
Preferably, described LncRNA primer also includes: ENST00000568243 primer, uc001gch.1 primer, NR_047562 primer, ENST00000442037 primer and NR_038125 primer.
It is furthermore preferred that ENST00000568243 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:21, primer after the sequence such as quantitative PCR shown in SEQIDNo:22；Uc001gch.1 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:23, primer after the sequence such as quantitative PCR shown in SEQIDNo:24；NR_047562 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:25, primer after the sequence such as quantitative PCR shown in SEQIDNo:26；ENST00000442037 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:27, primer after the sequence such as quantitative PCR shown in SEQIDNo:28；NR_038125 primer includes before the sequence such as quantitative PCR shown in SEQIDNo:29 primer after primer, the sequence such as quantitative PCR shown in SEQIDNo:30.
LncRNA primer described in fourth aspect present invention offer, the purposes in the diagnosing tumor medicine being combined in preparation or screening human lung adenocarcinoma and/or Human colorectal carcinoma of label.
Fifth aspect present invention provides the tumor diagnosis kit of a kind of human lung adenocarcinoma and/or Human colorectal carcinoma, including the combination of described LncRNA primer, label.
Preferably, described test kit may also include dNTP, random primer, reducing agent, RNase inhibitor, reverse transcription, MgCl2With one or more the combination in PCR buffer etc..
Sixth aspect present invention provides a kind of LncRNA chip detecting human lung adenocarcinoma and/or Human colorectal carcinoma, it is characterized in that, described LncRNA chip includes the probe of solid phase carrier and the LncRNA biomarker as claimed in claim 1 that is fixed on solid phase carrier.
Those skilled in the art rule of thumb, can be designed to detect the probe of relevant LncRNA biomarker, such as the fluorescent probe etc. that this area has been widely used.Specifically, described fluorescent probe can be oligonucleotide probe, and described oligonucleotide probe corresponds to the part or all of sequence of LncRNA.
Human lung adenocarcinoma provided by the present invention and/or Human colorectal carcinoma diagnosis LncRNA biomarker, can be used to distinguish people's early stage adenocarcinoma of lung and Human colorectal carcinoma.It distinguishes the AUC of early stage adenocarcinoma of lung and pairing normal lung tissue up to 0.978, significance individually diagnoses the AUC (p < 0.05) of early stage adenocarcinoma of lung higher than these 5 LncRNAs, its ROC curve shows the sensitivity of these 5 LncRNAs diagnosis early stage adenocarcinomas of lung and specificity respectively 92% and 98%, and significance is higher than the single LncRNA sensitivity for adenocarcinoma of lung diagnosis and specificity (p < 0.05).And its AUC of diagnosis for colorectal cancer sample also can reach 0.963, sensitivity and specificity respectively 94.4% and 88.9%, illustrate that the combination of LncRNAs provided by the present invention can also as the biomarker of colorectal cancer detection.
Accompanying drawing explanation
Fig. 1 is shown as 10 LncRNAs of present invention ROC curve figure joining together to distinguish training set (n=50) adenocarcinoma of lung and pairing normal lung tissue thereof；
Fig. 2-A is shown as 5 LncRNAs of present invention ROC curve figure joining together to distinguish training set (n=50) adenocarcinoma of lung and pairing normal lung tissue thereof；Fig. 2-B is shown as 5 LncRNAs of present invention ROC curve figure joining together to distinguish checking collection (n=63) adenocarcinoma of lung and pairing normal lung tissue thereof.
Fig. 3 is shown as 10 LncRNAs of the present invention and joins together to distinguish colorectal cancer and the ROC curve figure of normal colorectal carcinoma of matching thereof.
Detailed description of the invention
Below by way of specific instantiation, embodiments of the present invention being described, those skilled in the art the content disclosed by this specification can understand other advantages and effect of the present invention easily.The present invention can also be carried out by additionally different detailed description of the invention or apply, and the every details in this specification based on different viewpoints and application, can also carry out various modification or change under the spirit without departing from the present invention.
Before further describing the specific embodiment of the invention, it should be appreciated that protection scope of the present invention is not limited to following specific specific embodiments；It is also understood that the term used in the embodiment of the present invention is to describe specific specific embodiments, rather than in order to limit the scope of the invention；In specification and claims of the present invention, unless additionally explicitly pointed out in literary composition, singulative " ", " one " and " this " include plural form.
When embodiment provides numerical range, it should be appreciated that unless the present invention is otherwise noted, between two end points and two end points of each numerical range, any one numerical value all can be selected for.Unless otherwise defined, the same meaning that all technology used in the present invention and scientific terminology and those skilled in the art of the present technique are generally understood that.Except the concrete grammar used in embodiment, equipment, material, record according to those skilled in the art's grasp to prior art and the present invention, it is also possible to use similar with the method described in the embodiment of the present invention, equipment, material or that be equal to any method of prior art, equipment and material to realize the present invention.
Unless otherwise indicated, the experimental technique that disclosed in this invention, detection method, preparation method all adopt the conventional molecular biology of the art, biochemistry, chromatin Structure and analysis, analytical chemistry, cell are cultivated, the routine techniques of recombinant DNA technology and association area.These technology existing improving in existing document illustrates, specifically can referring to the MOLECULARCLONING:ALABORATORYMANUAL such as Sambrook, Secondedition, ColdSpringHarborLaboratoryPress, 1989andThirdedition, 2001；Ausubel etc., CURRENTPROTOCOLSINMOLECULARBIOLOGY, john wiley & sons, NewYork, 1987andperiodicupdates；TheseriesMETHODSINENZYMOLOGY, AcademicPress, SanDiego；Wolffe, CHROMATINSTRUCTUREANDFUNCTION, Thirdedition, AcademicPress, SanDiego, 1998；METHODSINENZYMOLOGY, Vol.304, Chromatin (P.M.WassarmanandA.P.Wolffe, eds.), AcademicPress, SanDiego, 1999；And METHODSINMOLECULARBIOLOGY, Vol.119, ChromatinProtocols (P.B.Becker, ed.) HumanaPress, Totowa, 1999 etc..
Embodiment 1
1 clinical sample is collected:
The early stage adenocarcinoma of lung frost flesh tissue specimen achieved during collecting Zhongshan Hospital Attached to Fudan Univ 2011-2014 and pairing normal lung tissue 113 thereof are right.All patients all have informed consent to participating in scientific research.
2LncRNA quantitative PCR experiment:
2.1RNA extracting and quantitative PCR
Utilize Trizol extracted total RNA from frozen tissue, with micro-volume spectrophotometer, RNA is carried out quantitatively.
2.2 reference genes and primer
The primer sequence of reference gene selection GAPDH, GAPDH and one group of LncRNA biomarker provided by the present invention is as shown in table 1:
The primer sequence that table 1 quantitative PCR uses
2.3 reverse transcription reactions
Using SuperScript III FirstStrandSynthesisSystem test kit to carry out reverse transcription, RNA initial amount is 1 μ g, and the consumption of reverse transcription reaction component is as shown in table 2, and reaction condition: hatch 5min at 65 DEG C at least places 1min on ice after completing；Adding reverse transcription reaction mixing liquid again in products therefrom, hatch 10min respectively, hatch 50min at 50 DEG C, hatch 5min at 85 DEG C after mixing at 25 DEG C, the consumption of reverse transcription reaction mixing liquid is as shown in table 3；Adding 1 μ lRNaseH after completing in each reaction products therefrom, after hatching 20min at 37 DEG C, cryopreservation is standby.
Table 2 reverse transcription reaction component
Table 3 reverse transcription reaction mixing liquid (mix)
2.4 real-time quantitative PCR reactions
Quantitative PCR uses LightCycler480SYBRGreen I master, and quantitative instrument is LightCycler480.Reaction system is as shown in table 4, and reaction condition step as shown in table 5, each real-time quantitative PCR react and to complying three repetitions:
Table 4 real-time quantitative PCR premixed liquid
Table 5 real-time quantitative PCR thermal cycle reference value
Use SPSS17.0 software that data are carried out statistical analysis.Data represent with the form of mean+SD, unless there are special explanation.Adenocarcinoma of lung matches the method that the differential expression statistics of lncRNA uses paired-sample t test in normal lung tissue with it, and all p values are bilateral, and p < 0.05 is considered statistically significant.
2.510 LncRNAs distinguish adenocarcinoma of lung and the capability evaluation of pairing normal lung tissue thereof
We utilize ROC curve to distinguish adenocarcinoma of lung and the ability of pairing normal lung tissue thereof to assess these 10 LncRNAs (gene ENST00000568243, uc001gch.1, ENST00000434223, uc004bbl.1, NR_047562, ENST00000540136, ENST00000442037, NR_038125, NR_034174 and uc001gzl.3).Single LncRNA is 0.721-0.853 for the AUC of adenocarcinoma of lung diagnosis, and sensitivity is 66-87%, and specificity is 62-86% (as shown in table 6).These 10 LncRNAs are joined together the diagnosis for 50 pairs of adenocarcinoma of lung samples by we, and its AUC can reach 0.994 (such as Fig. 1), and sensitivity and specificity are 96%.
610 LncRNAs of table diagnostic result in training set (50 pairs of samples)
1P value and AUC obtain with after reference gene GAPDH normalization.
2.6.15 individual LncRNAs distinguishes adenocarcinoma of lung and the capability evaluation of pairing normal lung tissue thereof
We utilize ROC curve to assess 5 LncRNAs (ENST00000540136, NR_034174, uc001gzl.3, uc004bbl.1 and ENST00000434223) and distinguish adenocarcinoma of lung and the ability of pairing normal lung tissue thereof.These 5 LncRNAs combine the AUC distinguishing early stage adenocarcinoma of lung and pairing normal lung tissue up to 0.978 (as shown in Fig. 2-A), and significance individually diagnoses the AUC (p < 0.05) of early stage adenocarcinoma of lung higher than these 5 LncRNAs.Under ROC curve, area shows the sensitivity of these 5 LncRNAs diagnosis early stage adenocarcinomas of lung and specificity respectively 92% and 98%, and significance is higher than the single LncRNA sensitivity for adenocarcinoma of lung diagnosis and specificity (p < 0.05).
2.6.25 individual LncRNAs distinguishes another group adenocarcinoma of lung and the capability evaluation of pairing normal lung tissue thereof
We are the detection characteristic of these 5 LncRNAs that checking filters out from training set in another set 63 example adenocarcinoma of lung sample and pairing normal lung tissue (checking collection) thereof.These 5 LncRNAs have significance differential expression (p < 0.001) in adenocarcinoma of lung and pairing normal lung tissue thereof are equal.Single LncRNA is 0.719-0.882 for detecting the AUC of adenocarcinoma of lung, and sensitivity is 77.8-85.2%, and specificity is 60.3-84.1% (table 7).These 5 LncRNAs joint-detection 63 are to the AUC of adenocarcinoma of lung sample up to 0.987 (Fig. 2-B), and sensitivity is 96.8%, and specificity is 92.1%, this equal significance power of test (p < 0.05) higher than any single LncRNA.Further, this group LncRNAs has similar power of test in two groups of independent samples (training set and checking collection), illustrates that this group LncRNAs can as the biomarker of adenocarcinoma of lung early stage detection.
75 LncRNA of table diagnostic result in checking collection (63 pairs of samples)
1P value and AUC obtain with after reference gene GAPDH normalization.
Embodiment 2
1 clinical sample is collected:
Collect the Shanghai Communications University's attached Ruijin Hospital colorectal cancer of 2013 frost flesh tissue specimen and the normal colorectal carcinoma 18 that matches is right.All patients all have informed consent to participating in scientific research.
2LncRNA quantitative PCR experiment:
2.1RNA extracting and quantitative PCR
Utilize Trizol extracted total RNA from frozen tissue, with micro-volume spectrophotometer, RNA is carried out quantitatively.
2.2 reference genes and primer
Reference gene selects GAPDH, shown in the table 1 in the primer sequence of reference gene and each LncRNA biomarker such as embodiment 1.
2.3 reverse transcription reactions, real-time quantitative PCR react
The concrete grammar of reverse transcription reaction, real-time quantitative PCR reaction, step are identical with embodiment 1 with reaction system.Use SPSS17.0 software that data are carried out statistical analysis.Data represent with the form of mean+SD, unless there are special explanation.Colorectal cancer matches the method that the differential expression statistics of lncRNA uses paired-sample t test in normal colorectal carcinoma with it, and all p values are bilateral, and p < 0.05 is considered statistically significant.
2.410 LncRNAs distinguish colorectal cancers and the capability evaluation of normal colorectal carcinoma of matching thereof
We utilize ROC curve to distinguish colorectal cancer and the ability of normal colorectal carcinoma of matching thereof to assess these 10 LncRNAs (gene ENST00000568243, uc001gch.1, ENST00000434223, uc004bbl.1, NR_047562, ENST00000540136, ENST00000442037, NR_038125, NR_034174 and uc001gzl.3).Single LncRNA is 0.750-0.889 for the AUC of diagnosis of colorectal carcinoma, and sensitivity is 66.7%-88.9%, and specificity is 55.6%-83.3% (as shown in table 8).These 10 LncRNAs are joined together the diagnosis for 18 pairs of colorectal cancer samples by we, its AUC can reach 0.963 (such as Fig. 3), sensitivity and specificity respectively 94.4% and 88.9%, illustrates that these LncRNAs completely can as the biomarker of colorectal cancer detection.
Diagnostic result in 810 LncRNAs colorectal cancers of table (18 pairs of samples)
1P value and AUC obtain with after reference gene GAPDH normalization.
The above; it is only presently preferred embodiments of the present invention; not to any formal and substantial restriction of the present invention; should be understood that; for those skilled in the art; under the premise without departing from the inventive method, also can making some improvement and supplement, these improve and supplement and also should be regarded as protection scope of the present invention.All those skilled in the art, without departing from the spirit and scope of the present invention, the equivalent variations of a little change, modification and the differentiation made when available disclosed above technology contents, it is the Equivalent embodiments of the present invention；Meanwhile, all change of any equivalent variations, modification and differentiation above-described embodiment made according to the substantial technological of the present invention, all still fall within the scope of technical scheme.
Claims (10)
1. LncRNA biomarker is used in lineup's adenocarcinoma of lung and/or Human colorectal carcinoma diagnosis, and described LncRNA biomarker includes: uc001gzl.3, ENST00000434223, uc004bbl.1, ENST00000540136 and NR_034174；
The sequence of described uc001gzl.3 is such as shown in SeqIDNo:1；
The sequence of described ENST00000434223 is such as shown in SeqIDNo:2；
The sequence of described uc004bbl.1 is such as shown in SeqIDNo:3；
The sequence of described ENST00000540136 is such as shown in SeqIDNo:4；
The sequence of described NR_034174 is such as shown in SeqIDNo:5.
2. LncRNA biomarker is used in human lung adenocarcinoma as claimed in claim 1 and/or Human colorectal carcinoma diagnosis, it is characterised in that described human lung adenocarcinoma behaviour early stage adenocarcinoma of lung, described Human colorectal carcinoma behaviour early stage colorectal cancer.
3. LncRNA biomarker is used in human lung adenocarcinoma as claimed in claim 1 and/or Human colorectal carcinoma diagnosis, it is characterized in that, described LncRNA biomarker also includes: ENST00000568243, uc001gch.1, NR_047562, ENST00000442037 and NR_038125；
The sequence of described ENST00000568243 is such as shown in SeqIDNo:6；
The sequence of described uc001gch.1 is such as shown in SeqIDNo:7；
The sequence of described NR_047562 is such as shown in SeqIDNo:8；
The sequence of described ENST00000442037 is such as shown in SeqIDNo:9；
The sequence of described NR_038125 is such as shown in SeqIDNo:10.
4. the purposes in the diagnosing tumor medicine of screening human lung adenocarcinoma and/or Human colorectal carcinoma of the LncRNA biomarker as described in claim 1-3 any claim.
5. the compositions of lineup's adenocarcinoma of lung and/or Human colorectal carcinoma diagnosis LncRNA primer, label, described LncRNA primer includes: the reverse transcription primer of LncRNA, uc001gzl.3 primer, ENST00000434223 primer, uc004bbl.1 primer, ENST00000540136 primer, NR_034174 primer；
The sequence of described uc001gzl.3 is such as shown in SeqIDNo:1；
The sequence of described ENST00000434223 is such as shown in SeqIDNo:2；
The sequence of described uc004bbl.1 is such as shown in SeqIDNo:3；
The sequence of described ENST00000540136 is such as shown in SeqIDNo:4；
The sequence of described NR_034174 is such as shown in SeqIDNo:5；
Uc001gzl.3 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:11, primer after the sequence such as quantitative PCR shown in SEQIDNo:12；ENST00000434223 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:13, primer after the sequence such as quantitative PCR shown in SEQIDNo:14；Uc004bbl.1 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:15, primer after the sequence such as quantitative PCR shown in SEQIDNo:16；ENST00000540136 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:17, primer after the sequence such as quantitative PCR shown in SEQIDNo:18；NR_034174 primer includes before the sequence such as quantitative PCR shown in SEQIDNo:19 primer after primer, the sequence such as quantitative PCR shown in SEQIDNo:20.
6. the compositions of lineup's adenocarcinoma of lung as claimed in claim 5 and/or Human colorectal carcinoma diagnosis LncRNA primer, label, it is characterised in that the reverse transcription primer of described LncRNA is random primer.
7. the compositions of lineup's adenocarcinoma of lung as claimed in claim 5 and/or Human colorectal carcinoma diagnosis LncRNA primer, label, it is characterized in that, described LncRNA primer also includes: ENST00000568243 primer, uc001gch.1 primer, NR_047562 primer, ENST00000442037 primer and NR_038125 primer；
The sequence of described ENST00000568243 is such as shown in SeqIDNo:6；
The sequence of described uc001gch.1 is such as shown in SeqIDNo:7；
The sequence of described NR_047562 is such as shown in SeqIDNo:8；
The sequence of described ENST00000442037 is such as shown in SeqIDNo:9；
The sequence of described NR_038125 is such as shown in SeqIDNo:10；
ENST00000568243 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:21, primer after the sequence such as quantitative PCR shown in SEQIDNo:22；Uc001gch.1 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:23, primer after the sequence such as quantitative PCR shown in SEQIDNo:24；NR_047562 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:25, primer after the sequence such as quantitative PCR shown in SEQIDNo:26；ENST00000442037 primer includes primer before the sequence such as quantitative PCR shown in SEQIDNo:27, primer after the sequence such as quantitative PCR shown in SEQIDNo:28；NR_038125 primer includes before the sequence such as quantitative PCR shown in SEQIDNo:29 primer after primer, the sequence such as quantitative PCR shown in SEQIDNo:30.
8. the compositions purposes in the diagnosing tumor medicine preparing human lung adenocarcinoma and/or Human colorectal carcinoma of LncRNA primer as described in claim 5-7 any claim, label.
9. a tumor diagnosis kit for human lung adenocarcinoma and/or Human colorectal carcinoma, including the compositions of the LncRNA primer as described in claim 5-7 any claim, label.
10. the LncRNA chip detecting human lung adenocarcinoma and/or Human colorectal carcinoma, it is characterised in that described LncRNA chip includes the probe of solid phase carrier and the LncRNA biomarker as described in claim 1-3 any claim that is fixed on solid phase carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410397937.7A CN104131108B (en) | 2014-08-13 | 2014-08-13 | LncRNA biomarker is used in lineup's adenocarcinoma of lung and Human colorectal carcinoma diagnosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410397937.7A CN104131108B (en) | 2014-08-13 | 2014-08-13 | LncRNA biomarker is used in lineup's adenocarcinoma of lung and Human colorectal carcinoma diagnosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104131108A CN104131108A (en) | 2014-11-05 |
| CN104131108B true CN104131108B (en) | 2016-06-29 |
Family
ID=51803957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410397937.7A Expired - Fee Related CN104131108B (en) | 2014-08-13 | 2014-08-13 | LncRNA biomarker is used in lineup's adenocarcinoma of lung and Human colorectal carcinoma diagnosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104131108B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105462974B (en) * | 2015-02-09 | 2018-06-01 | 苏州大学 | Participate in long-chain non-coding RNA and its application of human body cell ionising radiation stress reaction |
| CN105441447B (en) * | 2015-02-09 | 2018-05-29 | 苏州大学 | Participate in long-chain non-coding RNA and its application of human body cell ionising radiation stress reaction |
| CN105441433B (en) * | 2015-02-09 | 2018-06-01 | 苏州大学 | Participate in long-chain non-coding RNA and its application of human body cell ionising radiation stress reaction |
| CN104673797B (en) * | 2015-02-09 | 2018-02-02 | 苏州大学 | Participate in long-chain non-coding RNA and its application of human body cell ionising radiation stress reaction |
| CN105463070B (en) * | 2015-07-08 | 2018-12-28 | 上海市同仁医院 | Application of the UCA1 gene in preparation diagnosis colorectal cancer product |
| CN105219770B (en) * | 2015-11-03 | 2018-09-25 | 中国科学院上海微系统与信息技术研究所 | Lineup's lung squamous cancer diagnosis LncRNA biomarkers |
| CN106295246A (en) * | 2016-08-07 | 2017-01-04 | 吉林大学 | Find the lncRNA relevant to tumor and predict its function |
| CN106119405B (en) * | 2016-08-31 | 2019-11-12 | 广州万德基因医学科技有限公司 | A kind of prognostic markers object of lung cancer, the method and application for using label prediction lung cancer for prognosis |
| CN107190052B (en) * | 2017-01-25 | 2019-02-12 | 河北医科大学第四医院（河北省肿瘤医院） | The purposes of LOC101928926 gene |
| CN106929577B (en) * | 2017-03-06 | 2020-05-26 | 山东省立医院 | lncRNA biomarker related to lung adenocarcinoma |
| CN106702009B (en) * | 2017-03-06 | 2021-07-02 | 青岛泱深生物医药有限公司 | Application of gene related to lung adenocarcinoma |
| CN107043823B (en) * | 2017-05-26 | 2020-05-12 | 郴州市第一人民医院 | Tumor marker related to colorectal cancer and application |
| CN108950001B (en) * | 2018-08-31 | 2020-08-11 | 青岛泱深生物医药有限公司 | Molecular marker related to occurrence and development of rectal adenocarcinoma |
| CN109266746B (en) * | 2018-09-17 | 2020-04-28 | 南京医科大学 | Primer pair for amplifying LINC02253 gene and application thereof |
| CN111455052B (en) * | 2020-04-21 | 2022-01-28 | 首都医科大学附属北京友谊医院 | Exosome RNA molecular marker combination for early diagnosis of colorectal cancer and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103146693A (en) * | 2013-02-26 | 2013-06-12 | 中南大学 | Long chain non-coding RNA (Ribonucleic Acid) gene and application method thereof |
| CN103237901A (en) * | 2010-03-01 | 2013-08-07 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarkers for theranostics |
| CN103952475A (en) * | 2014-03-27 | 2014-07-30 | 南京市第一医院 | Novel esophageal carcinoma (EC) marker gene detection and application |
| CN103952474A (en) * | 2014-03-27 | 2014-07-30 | 南京市第一医院 | Esophageal carcinoma (EC) diagnosis marker and application method thereof |
-
2014
- 2014-08-13 CN CN201410397937.7A patent/CN104131108B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103237901A (en) * | 2010-03-01 | 2013-08-07 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarkers for theranostics |
| CN103146693A (en) * | 2013-02-26 | 2013-06-12 | 中南大学 | Long chain non-coding RNA (Ribonucleic Acid) gene and application method thereof |
| CN103952475A (en) * | 2014-03-27 | 2014-07-30 | 南京市第一医院 | Novel esophageal carcinoma (EC) marker gene detection and application |
| CN103952474A (en) * | 2014-03-27 | 2014-07-30 | 南京市第一医院 | Esophageal carcinoma (EC) diagnosis marker and application method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104131108A (en) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104131108B (en) | LncRNA biomarker is used in lineup's adenocarcinoma of lung and Human colorectal carcinoma diagnosis | |
| Kuhlmann et al. | Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer | |
| CN104877998B (en) | The primer pair and kit of the long-chain non-coding RNA expression in long-chain non-coding RNA and detection cell and tissue | |
| WO2017124854A1 (en) | Primers, probe and kit for detecting ndrg4 gene methylation for early diagnosis of intestinal cancer | |
| CN107488726B (en) | Kidney cancer prognosis evaluation biomarker and detection reagent and application thereof | |
| CN106148529B (en) | LncRNA marker related to gastric cancer, special detection primer, detection method, kit and application thereof | |
| JP2019527544A (en) | Molecular marker, reference gene, and application thereof, detection kit, and detection model construction method | |
| CN105219770B (en) | Lineup's lung squamous cancer diagnosis LncRNA biomarkers | |
| CN106811525B (en) | Kit and system for predicting early postoperative recurrence of stage III gastric cancer patient | |
| CN111139300B (en) | Application of group of colon cancer prognosis related genes | |
| Yu et al. | Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules | |
| CN106350600A (en) | Application of LOC80054 in diagnosis or prognosis of pancreatic cancer | |
| Qi et al. | Downregulation of microRNA-382 is associated with poor outcome of esophageal squamous cell carcinoma | |
| Wei et al. | The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids | |
| CN104152556B (en) | A kind of test kit and application judging Herceptin adjuvant treatment of breast cancer curative effect | |
| CN105647923B (en) | Serum miRNA marker related to liver cancer prognosis and application of detection kit thereof | |
| CN106191055A (en) | A kind of non-small cell lung carcinoma marker, detectable and test kit | |
| CN107630093A (en) | For the reagent of diagnosing liver cancer, kit, detection method and purposes | |
| CN108624693A (en) | Applications of the miR-577 in preparing diagnosis of nephropathy marker | |
| CN107641649B (en) | Primer pair, kit and method for detecting stability of NR27 locus of microsatellite | |
| CN104450702B (en) | A kind of Serum miRNA biomarker composition and application | |
| CN102839172A (en) | HIV (Human immunodeficiency virus) infection disease progression molecule marker miR-503 | |
| CN102605042A (en) | Application of miR-378 biomarker in detection and diagnosis of gastric cancer | |
| EP2247754A1 (en) | Colon cancer associated transcript 1 (ccat1) as a cancer marker | |
| CN110257514B (en) | Novel esophageal cancer blood miRNA marker and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160629 Termination date: 20180813 |